{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05844033",
            "orgStudyIdInfo": {
                "id": "23-105"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Biomarker for Infection Risk in CLL and MM",
            "officialTitle": "Biomarker for Infection Risk in Chronic Lymphocytic Leukemia and Multiple Myeloma",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "biomarker-for-infection-risk-in-cll-and-mm"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-13",
            "studyFirstSubmitQcDate": "2023-05-03",
            "studyFirstPostDateStruct": {
                "date": "2023-05-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jacob Soumerai, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Takeda",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).",
            "detailedDescription": "The goal of this research study is to identify an antigen-specific antibody profiling biomarker associated with increased risk of any infections in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).\n\nResearch procedures including screening for eligibility, clinic visits, and blood tests.\n\nThis involves performing blood tests which detect antibodies directed against specific pathogens and measure their functional capacity, and collecting information about outcomes in patients.\n\nParticipation in this research study is expected to last 2 years.\n\nIt is expected that about 150 people CLL or MM will take part in this research study, and this will predominantly include people with CLL/SLL.\n\nTakeda is supporting this research study by providing funding."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma",
                "Chronic Lymphocytic Leukemia"
            ],
            "keywords": [
                "Multiple Myeloma",
                "Chronic Lymphocytic Leukemia"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITHOUT_DNA",
                "description": "Antibody profiling and functional assays (advanced testing which detects antibodies directed against specific pathogens and measures their functional capacity)"
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Chronic Lymphocytic Leukemia and Multiple Myeloma Participants",
                    "description": "150 participants will be screened for an antigen-specific antibody profiling biomarker that is associated with an increased risk of any infections.\n\nStudy procedures include in-person or virtual appointments every 3 months for 2 years, some of which will also include bloodwork:\n\n* In-person or virtual appointments with study staff for months 4, 10, 16, and 22 Day 1.\n* In-person or virtual appointments with study staff for months 7, 13, 19, and 25 Day 1 with blood tests.",
                    "interventionNames": [
                        "Other: Screening"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Screening",
                    "description": "Blood tests",
                    "armGroupLabels": [
                        "Chronic Lymphocytic Leukemia and Multiple Myeloma Participants"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of All-Grade Infections For All Participants",
                    "description": "Defined as the number of All-Grade infections per person-years per CTCAE version 5.0 for all participants.",
                    "timeFrame": "up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Grade \u22653 Infections For All Participants",
                    "description": "Defined as the number of Grade \u22653 infections per person-years per CTCAE version 5.0 for all participants.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Number of All-Grade Infections for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) Participants",
                    "description": "Defined as the number of All-Grade infections per person-years per CTCAE version 5.0 for CLL/SLL participants.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Number of Grade \u22653 Infections for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Participants",
                    "description": "Defined as the number of Grade \u22653 infections per person-years per CTCAE version 5.0 for CLL and SLL participants.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Number of All-Grade Infections for Multiple Myeloma (MM) Participants",
                    "description": "Defined as the number of All-Grade infections per person-years per CTCAE version 5.0 for MM participants.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Number of Grade \u22653 Infections for Multiple Myeloma (MM) Participants",
                    "description": "Defined as the number of Grade \u22653 infections per person-years per CTCAE version 5.0 for MM participants.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Proportion of patients who develop symptomatic hypogammaglobulinemia in CLL/SLL or MM.",
                    "description": "Defined as any incident in which immunoglobulin replacement therapy is administered to an participant who develops symptomatic hypogammaglobulinemia with Immunoglobulin G \\<600mg/dL and either 1) \u22652 associated infections within a 6-month period, or 2) any grade \u22653 associated infection.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Proportion of patients who develop asymptomatic hypogammaglobulinemia in CLL/SLL or MM.",
                    "description": "Defined as the proportion of all participants who develop symptomatic hypogammaglobulinemia.",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults \u226518 years of age.\n* Diagnosis of Rai stage I-IV chronic lymphocytic leukemia or small lymphocytic lymphoma or multiple myeloma.\n* Subjects must be able to consent to clinical trial, or documented health care proxy agent able to consent on behalf of participant.\n\nExclusion Criteria:\n\n* Subjects must not have received IVIG administration within 6 calendar months of registration or have planned immunoglobulin replacement therapy by treating investigator at time of registration.\n* Subjects with chronic lymphocytic leukemia or small lymphocytic lymphoma must not be Rai stage 0.\n* Subjects with multiple myeloma must not have smoldering myeloma or solitary plasmacytoma with or without minimal marrow involvement.\n* Subjects must not have undergone prior autologous, allogeneic stem cell, or solid organ transplant.\n* Subjects must not have any active systemic infection requiring ongoing antimicrobial treatment (prophylactic antimicrobial allowed) at time of registration.\n* Subjects must have no known history of HIV, primary immune deficiency disorder, nor be taking a concurrent immune suppressing medication at time of registration. Treatment for CLL/SLL or MM, CLL/SLL related autoimmune phenomenon, or physiologic dosing of corticosteroids (5mg/day prednisone/equivalent or lower) is permitted.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Diagnoses of Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Multiple Myeloma.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jacob Soumerai, MD",
                    "role": "CONTACT",
                    "phone": "617-724-4000",
                    "email": "jsoumerai@mgh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jacob Soumerai, MD",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital Cancer Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jacob Soumerai, MD",
                            "role": "CONTACT",
                            "phone": "617-724-4000",
                            "email": "jsoumerai@mgh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \\[contact information for Sponsor Investigator or designee\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL"
            ],
            "timeFrame": "Data can be shared no earlier than 1 year following the date of publication.",
            "accessCriteria": "Contact the Partners Innovations team at http://www.partners.org/innovation."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000015451",
                    "term": "Leukemia, Lymphocytic, Chronic, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000015448",
                    "term": "Leukemia, B-Cell"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18116",
                    "name": "Leukemia, Lymphocytic, Chronic, B-Cell",
                    "asFound": "Chronic Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18115",
                    "name": "Leukemia, B-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1308",
                    "name": "Chronic Lymphocytic Leukemia",
                    "asFound": "Chronic Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}